GSK Investigates 'Different Pricing Options' Following CHMP Nod For 'Bubble Boy' Gene Therapy
This article was originally published in Scrip
GlaxoSmithKline PLC's 'bubble boy' treatment has been given a positive opinion by the European Medicines Agency's advisory committee.
You may also be interested in...
Milan, Italy is a hotspot in Europe for gene therapy research, and the European VC Sofinnova Partners is backing the latest start-up aimed at metabolic and primary immunodeficiencies.
The Atlas and Third Rock-backed startup Magenta raised a $48.5m Series A round to develop drugs that improve three key steps in the stem cell transplant process. Turnstone, Glycomine and Syntimmune also brought in a combined $61.4m new funding during the first half of November.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.